Research and Clinical Trials on Quetiapine (Seroquel)
This list of current clinical research trials on Quetiapine (Seroquel) is followed by a short set of abstracts from the most recent research articles published on the drug.
Quetiapine (Seroquel) Clinical Research Trials
From our searchable database at ClinicalTrialsFeeds.org, this list includes all the latest information about clinical trials involving Quetiapine (Seroquel).
- Quetiapine Fumarate Immediate Release (IR) Versus Extended Release (XR) Dose Escalation Comparison
Status: Not yet recruiting, Condition Summary: Healthy Volunteers - A Double Blind, Placebo Controlled Trial of Quetiapine in Anorexia Nervosa, a Dual Site Study
Status: Recruiting, Condition Summary: Anorexia Nervosa - Quetiapine for Mania In Preschool Children 4 to 6 Years of Age With Bipolar Disorder
Status: Recruiting, Condition Summary: Bipolar Disorder; Mania - Study of Efficacy and Safety of Seroquel (Quetiapine Fumarate) as Mono-Therapy for Acute Schizophrenic
Status: Completed, Condition Summary: Schizophrenia - Quetiapine Treatment for Symptoms Associated With Borderline Personality Disorder
Status: Completed, Condition Summary: Borderline Personality Disorder - Double-Blind Placebo-Controlled Trial of Quetiapine in Anorexia Nervosa
Status: Recruiting, Condition Summary: Anorexia Nervosa - Quetiapine (Seroquel) Maintenance Treatment in Early Onset Bipolar Spectrum Disorders
Status: Completed, Condition Summary: Bipolar Disorder - Quetiapine in Co-Morbid Depressive and Anxiety Disorders
Status: Not yet recruiting, Condition Summary: Major Depressive Disorder; Dysthymic Disorder; Anxiety Disorders; Generalized Anxiety Disorder; Social Anxiety Disorder; Panic Disorder; Post-Traumatic Stress Disorder - Quetiapine Fumarate (Seroquel) as Mono-Therapy or Adjunct to Lithium in the Treatment of Patients With Acute Mania in Bipolar Disorder
Status: Recruiting, Condition Summary: Acute Mania in Bipolar Disorder - Quetiapine XR in Bipolar Patients With Comorbid Generalized Anxiety Disorder (GAD)
Status: Recruiting, Condition Summary: Bipolar Disorder; Anxiety; Anxiety Disorders; Substance Use Disorders - Quetiapine Induced Neuroplasticity in First-Episode Schizophrenic Patients
Status: Recruiting, Condition Summary: Schizophrenia - Trial of Seroquel SR for Alcohol Dependence and Comorbid Anxiety
Status: Recruiting, Condition Summary: Alcoholism; Anxiety Disorders; Generalized Anxiety Disorder; Post-Traumatic Stress Disorder; Panic Disorder; Obsessive-Compulsive Disorder - Comparison of the Subjective Well-Being and Tolerability of Quetiapine XR to Risperidone
Status: Recruiting, Condition Summary: Schizophrenic Disorders - A Canadian Study Evaluating the Clinical Benefit of SEROQUEL XR in Subjects With Schizophrenia
Status: Not yet recruiting, Condition Summary: Schizophrenia - A 4-Week, Randomized, Rater-Blinded, Parallel Study to Evaluate Quetiapine in Improving Sleep Quality of Schizophrenia
Status: Recruiting, Condition Summary: Schizophrenia
Get These Clinical Trials as a Newsfeed
Current Research Literature on Quetiapine (Seroquel)
Here are abstracts for some of the latest research articles to have appeared on Quetiapine (Seroquel):
Biological perspectives incarcerated care and quetiapine abuse.
Perspect Psychiatr Care. 2008 Jul; 44(3): 202-6
Keltner NL, Vance DE
J Clin Psychiatry. 2008 Jun 17; e1-e9
Croarkin PE, Emslie GJ, Mayes TL
OBJECTIVE: To retrospectively examine published cases of neuroleptic malignant syndrome (NMS) in patients aged 18 and below who had been treated with atypical antipsychotics (clozapine, risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazole). DATA SOURCES: Information was collected via MEDLINE searches in February 2006 and May 2007. The term neuroleptic malignant syndrome was used and cross-referenced with individual atypical antipsychotics. The authors also contacted (by telephone and in writing) pharmaceutical companies that produce and market atypical antipsychotics for any data on NMS. STUDY SELECTION: Twenty case reports (written in English only and published from 1991-2007) were identified and reviewed. These publications all described symptoms of NMS in patients aged 18 or younger who had been treated with atypical antipsychotics. DATA EXTRACTION: Data were reviewed and compared with 3 diagnostic criteria (DSM-IV-TR, Levenson's, and Caroff and Mann's) for NMS. Interventions and outcomes were also reviewed. DATA SYNTHESIS: Twenty case reports were identified and presented with a descriptive approach. Sixteen cases met criteria for NMS, with at least 1 of the diagnostic sets utilized. The majority of cases involved male subjects. All patients recovered. CONCLUSIONS: Young patients can develop NMS during treatment with atypical antipsychotics. Symptoms of this disorder are consistent with those described in adults. Although NMS is rare in this population, clinicians should maintain a high index of suspicion. Appropriate caution in treating children and adolescents with any antipsychotic is warranted.
Weight change in Parkinson and Alzheimer patients taking atypical antipsychotic drugs.
J Neurol Sci. 2008 Jun 13;
Sitburana O, Rountree S, Ondo WG
Atypical antipsychotics (AA) are generally associated with weight gain. We determined body mass index (BMI) change in Parkinson's disease (PD) before and after taking AA and compared against PD controls and Alzheimer's disease (AD) patients on AA. In 66 consecutive PD subjects started on AA who had accurate weights for more than 6 months before and after initiation of AA, we compared weight change before and after AA use, against a control group of sixty-one sex-matched PD subjects, and against twenty-eight AD subjects taking AA. A linear regression model was created to compare weight changes. Fifty-nine PD subjects had complete data, quetiapine (n=53) and clozapine (n=6). The mean BMI change in the period before starting AA was 0.00 kg/m(2)/month over 1.95+/-1.41 years. After starting AA, subjects lost 0.03 kg/m(2)/month (95% CI 0.62-1.21, P
Demonstration of an anti-oxidative stress mechanism of quetiapine.
FEBS J. 2008 Jun 12;
Xu H, Wang H, Zhuang L, Yan B, Yu Y, Wei Z, Zhang Y, Dyck LE, Richardson SJ, He J, Li X, Kong J, Li XM
We have shown that quetiapine, a new antipsychotic drug, protects cultured cells against oxidative stress-related cytotoxicities induced by amyloid beta (Abeta)25-35, and that quetiapine prevents memory impairment and decreases Abeta plaques in the brains of amyloid precursor protein (APP)/presenilin-1 (PS-1) double-mutant mice. The aim of this study was to understand why quetiapine has these protective effects. Because the cytotoxicity of both Abeta(25-35) and Abeta(1-40) requires fibril formation, our first experiments determined the effect of quetiapine on Abeta(25-35) aggregation. Quetiapine inhibited Abeta(25-35) aggregation in cell-free aqueous solutions and blocked the fibrillar aggregation of Abeta(25-35), as observed under an electron microscope. We then investigated why quetiapine inhibits Abeta(25-35) aggregation. During the aggregation of Abeta(25-35), a hydroxyl radical (OH(*)) was released, which in turn amplified Abeta(25-35) aggregation. Quetiapine blocked OH(*)-induced Abeta(25-35) aggregation and scavenged the OH(*) produced in the Fenton system and in the Abeta(25-35) solution, as analyzed using electron paramagnetic resonance spectroscopy. Furthermore, new compounds formed by quetiapine and OH(*) were observed in MS analysis. Finally, we applied Abeta(25-35) to PC12 cells to observe the effect of quetiapine on living cells. Abeta(25-35) increased levels of intracellular reactive oxygen species and calcium in PC12 cells and caused cell death, but these toxic effects were prevented by quetiapine. These results demonstrate an anti-oxidative stress mechanism of quetiapine, which contributes to its protective effects observed in our previous studies and explains the effectiveness of this drug for Alzheimer's disease patients with psychiatric and behavioral complications.
Clin Drug Investig. 2008; 28(7): 439-42
Savas HA, Yumru M, Ozen ME
BACKGROUND AND OBJECTIVE: While serotonin reuptake inhibitors (SRIs) are first-line pharmacological agents in the treatment of obsessive-compulsive disorder (OCD), 40-60% of patients with the disorder do not respond to these agents. This suggests that other neurotransmitters may play a role in OCD. In this regard, there has been particular interest in the dopaminergic system, with various antipsychotic drugs having been used as adjunctive therapy for refractory OCD. The aim of this study was to compare the efficacy of quetiapine and ziprasidone as adjuncts for treatment-resistant OCD. METHODS: A total of 24 OCD patients treated with either quetiapine (n = 15) or ziprasidone (n = 9) as adjunctive therapy to high-dose SRI treatment were included in this retrospective evaluation. Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) and Clinical Global Impression (CGI) scale scores were used to evaluate baseline clinical status and clinical improvement at 1, 2, 3 and 6 months of follow-up. RESULTS: Clinical improvement was established in 80% of the quetiapine group and in 44.4% of the ziprasidone group with an overall mean improvement rate on the Y-BOCS scale of 66.7%. Both Y-BOCS and CGI mean scores were higher in the ziprasidone group at 2, 3 and 6 months follow-up than in the quetiapine group. CONCLUSIONS: In the first reported study of its role in this setting, ziprasidone was found to be less effective than quetiapine in the treatment of refractory OCD.
Related Articles at CounsellingResource.com
From the Drugs and Mental Health section of our main blog:
- Placebo Pills for Children
- Long Live the Placebo!
- Easier Access to Clinical Trials and Research Abstracts
- Evidence for Effectiveness of Antidepressants Seems Underwhelming
- Shire Recalls Daytrana ADHD Patches in ‘Voluntary Market Withdrawal’
From the Medications section of ‘Ask the Psychologist’:
This page was last reviewed by , Friday, 4 July 2008.
The URL of this page is:
http://counsellingresource.com/medications/trials-and-research/quetiapine-research.html
